Canada-European Trade Agreement. Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
Legislative Proposal, Bill or Resolution, Policies or Program
The Bill formerly known as Bill C-393 (Canada Access to Medicines Regime) with respect to simplifying the process for pharmaceutical manufacturers to participate including sections on requirements, process, outcomes and responsibilities.
Legislative Proposal, Bill or Resolution, Regulation
Patent Act - lobby for changes on all rules and processes for the listing of generic pharmaceutical products.
Policies or Program, Regulation
Trade Agreements (NAFTA) North American Free Trade Agreement, WTO (World Trade Organization), European-Canada Free Trade Agreement policies, regulations,patents: with respect to terms, dispute settlements; pharmaceutical products policies, reviews/changes/updates; and all other changes that impact the ability to introduce products or export to other countries.
Regulation
Health Canada generic submissions review/approvals: with respect to the submission of new generic products to Health Canada and the resources, timing, structures and requirements needed to complete process.
Notice of compliance regulations (NOC): with respect to application of regulations, reviews/changes as it relates to the approval of generic drugs in Canada.
Communication Techniques
Written communication
Grass-roots communication
Government Institutions
Canadian Heritage (PCH)
Canadian International Trade Tribunal (CITT)
Competition Bureau Canada (COBU)
Competition Tribunal (CT)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Justice Canada (JC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Revenue Canada (RC)
Senate of Canada
Solicitor General Canada (SGC)
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 300 medicines to the healthcare system and exports these to 115 countries. Apotex's 2012 Research and Development (R&D) budget was $207 million - positioning it in the top 13 companies for all industrial sectors (20% of sales).
Responsible officer name and position during the period of this registration
Jeremy Desai,
President and CEO
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
150 Signet Drive
Toronto, ON M9L 1T9
Canada
Telephone number:
416-749-9300
Parent Company Information
Apotex Inc. is not a subsidiary of any other parent companies.